Elsevier

Life Sciences

Volume 56, Issue 1, November 1994, Pages PL27-PL32
Life Sciences

Pharmacology letter Accelerated communication
SR 142801, The first potent non-peptide antagonist of the tachykinin NK3 receptor

https://doi.org/10.1016/0024-3205(94)00413-MGet rights and content

Abstract

SR 142801 is the first potent and selective non-peptide antagonist of the tachykinin NK3 receptor. It inhibited [MePhe7]NKB binding to its receptor from various species, including humans. SR 142801 was a competitive antagonist of [MePhe7]NKB-mediated contractions of guinea-pig ileum and inhibited the acetylcholine release following the activation of the guinea-pig ileum tachykinin NK3 receptor. In vivo, SR 142801 potently inhibited the turning behaviour induced by intrastriatal injection of senktide in gerbils, and appears as a powerful tool for investigation of the physiological and pathological role of NKB and its NK3 receptor.

References (16)

  • RegoliD. et al.

    Life Sci.

    (1994)
  • Emonds-AltX. et al.

    Eur. J. Pharmacol.

    (1993)
  • Emonds-AltX. et al.

    Life Sci.

    (1992)
  • BodenP. et al.

    Bioorg. Med. Chem. Lett.

    (1994)
  • ChretienL. et al.

    Eur. J. Pharmacol.

    (1994)
  • PetitetF. et al.

    Biochem. Biophys. Res. Commun.

    (1993)
  • ChungF.Z. et al.

    Biochem. Biophys. Res. Commun.

    (1994)
  • BuellG. et al.

    FEBS Lett.

    (1992)
There are more references available in the full text version of this article.

Cited by (261)

  • Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact

    2019, Bioorganic and Medicinal Chemistry
    Citation Excerpt :

    The fused piperidine derivatives 4b–d were synthesized from a common substrate, 3-oxopiperidine derivative 7 (Scheme 1B). Reaction of ketone 7 with 1-azido-4-nitrobenzene provided 1,2,3-triazole 8.25 N1-arylation on triazole 8 proceeded by treatment of triazole 8 with 2-chloroquinoline in the presence of i-Pr2NEt to afford the desired 1-(quinolin-2-yl)triazole 9 after separation from a mixture of regioisomers.

  • Evidence for involvement of NK<inf>3</inf> receptors in the anxiogenic-like effect of SP6-11(C-terminal), a metabolite of substance P, in rats evaluated in the elevated plus-maze

    2016, Behavioural Brain Research
    Citation Excerpt :

    Species differences in the pharmacological characteristics of NK3 receptor antagonists further complicate investigations in animal models. For instance, the NK3 antagonist used in the current study, SR142801, is a selective and potent non-peptide antagonist at the human NK3 receptor (pA2 = 9.15) [62], but shows some species differences in binding to NK3 receptors. Firstly, SR1421801 has the highest affinity for the guinea pig NK3 receptor with a Ki value of 0.11 nM as compared to the rat (15 nM), gerbil (0.42 nM) and human (0.21 nM) NK3 receptors [61].

View all citing articles on Scopus
View full text